These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33872388)

  • 1. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Druggable genetic targets in endometrial cancer
    Lehrer S; Rheinstein PH
    Cancer Treat Res Commun; 2022; 30():100502. PubMed ID: 34933203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FBXW7, L1CAM, and TGM2 in endometrial cancer.
    Lehrer S; Rheinstein PH
    Cancer; 2021 Nov; 127(21):4103-4104. PubMed ID: 34324708
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to FBXW7, L1CAM, and TGM2 in endometrial cancer.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Nov; 127(21):4105. PubMed ID: 34324196
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
    Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
    EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
    Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
    Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of tumor suppressors changes the endometrial tumor spectrum.
    Mayo LD
    EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.
    Schirmer U; Fiegl H; Pfeifer M; Zeimet AG; Müller-Holzner E; Bode PK; Tischler V; Altevogt P
    BMC Cancer; 2013 Mar; 13():156. PubMed ID: 23530769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
    Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
    J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
    Baxter JS; Brough R; Krastev DB; Song F; Sridhar S; Gulati A; Alexander J; Roumeliotis TI; Kozik Z; Choudhary JS; Haider S; Pettitt SJ; Tutt ANJ; Lord CJ
    Mol Oncol; 2024 Feb; 18(2):369-385. PubMed ID: 37866880
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Close V; Close W; Kugler SJ; Reichenzeller M; Yosifov DY; Bloehdorn J; Pan L; Tausch E; Westhoff MA; Döhner H; Stilgenbauer S; Oswald F; Mertens D
    Blood; 2019 Feb; 133(8):830-839. PubMed ID: 30510140
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis.
    Giannini A; D'Oria O; Corrado G; Bruno V; Sperduti I; Bogani G; Laganà AS; Chiantera V; Caserta D; Vizza E
    Arch Gynecol Obstet; 2024 Mar; 309(3):789-799. PubMed ID: 37454351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-205 promotes epithelial-mesenchymal transition by targeting AKT signaling in endometrial cancer cells.
    Jin C; Liang R
    J Obstet Gynaecol Res; 2015 Oct; 41(10):1653-60. PubMed ID: 26446417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
    Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
    Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.